Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Amazon Secures 200 MW Wind Power Deals in Sweden 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Toyota Global Sales Fall as China Demand Slumps 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Add as a preferred source on Google
WATERTOWN, Mass., April 02, 2018 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the H. C. Wainwright Annual Global Life Sciences Conference on Monday, April 9 at 10:40 a.m. CEST at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
Live audio webcasts of the presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. Archived presentations will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multi-drug resistant pathogens highlighted as urgent public health threats by the Centers for Disease Control and Prevention. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which has completed phase 3 clinical trials and is under review for potential approval in complicated intra-abdominal infections by the United States Food and Drug Administration and the European Medicines Agency, and TP-271 and TP-6076, which are in phase 1 clinical trials. Eravacycline is an investigational product only and has not been approved for commercialization. Please visit www.tphase.com for more company information.
Investor Contacts:
Tetraphase Pharmaceuticals
Jennifer Viera
617-600-7040
[email protected]
Argot Partners
Maeve Conneighton
206-899-4940
[email protected]
Media Contact:
Sam Brown Inc.
Mike Beyer
312-961-2502
[email protected]
###
